Cover Image
市場調查報告書

BioCrea GmbH - 產品平台分析

BioCrea GmbH - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 309676
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
BioCrea GmbH - 產品平台分析 BioCrea GmbH - Product Pipeline Review - 2015
出版日期: 2015年11月30日 內容資訊: 英文 24 Pages
簡介

BioCrea GmbH 身為一個創藥廠商,正致力於開發最高等級中樞神經系統(CNS)補藥遞送方式。該公司基於獨家化合物庫、分子模組、醫藥品化學,以及高度篩檢技術,具備創藥方面的專業知識及技術。

本報告提供BioCrea GmbH 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

BioCrea GmbH 基本資料

BioCrea GmbH 概要

  • 主要資訊
  • 企業資料

BioCrea GmbH :R&D概要

  • 主要的治療範圍

BioCrea GmbH :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

BioCrea GmbH :開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

BioCrea GmbH :藥物簡介

  • Small Molecule to Inhibit PDE10 for Schizophrenia and Huntington's Disease
  • Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism
  • Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder
  • Small Molecule to Inhibit PDE4 for CNS Disorders
  • Small Molecules to Inhibit PDE2 and PDE10 for CNS Disorders
  • Stem Cell Therapy for Amyotrophic Lateral Sclerosis

BioCrea GmbH :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

BioCrea GmbH :總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07827CDB

Summary

Global Markets Direct's, 'BioCrea GmbH - Product Pipeline Review - 2015', provides an overview of the BioCrea GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BioCrea GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of BioCrea GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of BioCrea GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the BioCrea GmbH's pipeline products

Reasons to buy

  • Evaluate BioCrea GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of BioCrea GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the BioCrea GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of BioCrea GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioCrea GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of BioCrea GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • BioCrea GmbH Snapshot
    • BioCrea GmbH Overview
    • Key Information
    • Key Facts
  • BioCrea GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • BioCrea GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • BioCrea GmbH - Pipeline Products Glance
    • BioCrea GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • BioCrea GmbH - Drug Profiles
    • Small Molecule to Inhibit PDE10 for Schizophrenia and Huntington's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Amyotrophic Lateral Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • BioCrea GmbH - Pipeline Analysis
  • BioCrea GmbH - Pipeline Products by Target
  • BioCrea GmbH - Pipeline Products by Molecule Type
  • BioCrea GmbH - Pipeline Products by Mechanism of Action
  • BioCrea GmbH - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Small Molecule to Inhibit PDE4 for CNS Disorders
  • Small Molecules to Inhibit PDE2 and PDE10 for CNS Disorders
  • BioCrea GmbH - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • BioCrea GmbH, Key Information
  • BioCrea GmbH, Key Facts
  • BioCrea GmbH - Pipeline by Indication, 2015
  • BioCrea GmbH - Pipeline by Stage of Development, 2015
  • BioCrea GmbH - Monotherapy Products in Pipeline, 2015
  • BioCrea GmbH - Out-Licensed Products in Pipeline, 2015
  • BioCrea GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • BioCrea GmbH - Preclinical, 2015
  • BioCrea GmbH - Discovery, 2015
  • BioCrea GmbH - Pipeline by Target, 2015
  • BioCrea GmbH - Pipeline by Molecule Type, 2015
  • BioCrea GmbH - Pipeline Products by Mechanism of Action, 2015
  • BioCrea GmbH - Discontinued Pipeline Products, 2015

List of Figures

  • BioCrea GmbH - Pipeline by Top 10 Indication, 2015
  • BioCrea GmbH - Pipeline by Stage of Development, 2015
  • BioCrea GmbH - Monotherapy Products in Pipeline, 2015
  • BioCrea GmbH - Pipeline by Top 10 Target, 2015
  • BioCrea GmbH - Pipeline by Top 10 Molecule Type, 2015
  • BioCrea GmbH - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top